Tissue Factor, Tissue Factor Pathway Inhibitor and Cytoadhesive Molecules in Patients with an Acute Coronary Syndrome

Physiological Research

Volumn 52, Issue 6, 2003, Pages 719-728

  Maly M ^a   Vojacek J ^a   Hrabos V ^a   Kvasnicka J ^b   Salaj, P ^c   Durdil, V ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Acute coronary syndrome; Cytoadhesive molecules; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; STATINE DERIVATIVE; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CALCULATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY SINUS; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANGINA, UNSTABLE; CELL ADHESION MOLECULES; CORONARY ARTERIOSCLEROSIS; E-SELECTIN; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LINEAR MODELS; LIPOPROTEINS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; P-SELECTIN; THROMBOPLASTIN;

EID: 0346500570     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. ABILGAARD U: Relative roles of tissue factor pathway inhibitor and antithrombin in the control of thrombogenesis. Blood Coagul Fibrinolysis 6 (Suppl 1): S45-S49, 1995.
2. BARSTAD RM, HAMERS MJAG, KIERULF P, WESTWICK A-B, SAKARIASSEN KS: Procoagulant human monocytes mediate tissue factor/factor VIIa-dependent platelet-thrombus formation when exposed to flowing nonanticoagulated human blood. Arterioscler Tromb Vasc Biol 15: 11-16, 1995.
3. BRAUNWALD E: Unstable angina: a classification. Circulation 80: 410-414, 1989.
4. BROWN JR, KUTER DJ: The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients. Thromb Haemost 85: 979-985, 2001.
5. CAMICI M, SAGRIPANTI A: Tissue factor pathway inhibitor. Minerva Med 90: 25-32, 1999.
6. CELI A, PELLEGRINI B, LORENZET R, DE BLASI A, READY N, FURIE BC, FURIE B: P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 91: 8767-8771, 1994.
7. GEARING AHJ, NEWMAN W: Circulating adhesion molecules in disease. Immunology 14: 506-412, 1993.
8. GIESEN PL, RAUCH U, BOHRMANN B, KLING D, ROQUE M, FALLON JT, BADIMON JJ, HIMBER J, RIEDERER MA, NEMERSON Y: Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 96: 2311-2315, 1999.
9. GIRARD TJ, NICHOLSON NS: The role of tissue factor/factor VIIa in the pathophysiology of an acute thrombotic formation. Curr Opin Pharmacol 1: 159-63, 2001.
10. GORI AM, PEPE G, ATTANASIO M, FALCIANI M, ABBATE R, PRISCO D, FEDI S, GIUSTI B, BRUNELLI T, GIUSTI B, BRUNELLI T, COMEGLIO P, GENSINI GF, NERI SERNERI GG: Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb Haemost 81: 589-593, 1999.
11. HAMAMOTO T, YAMAMOTO M, NORDFANG O, PETERSEN JG, FOSTER DC, KISIEL W: Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces. J Biol Chem 268: 8704-8710, 1993.
12. HANSEN JB, SANDSET PM, HUSEBY KR, NORDOY A: Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 76: 703-709, 1996.
13. IAKHIAEV A, PENDURTHI UR, VOIGT J, EZBAN M, VIJAYA MOHAN RAO L: Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor. J Biol Chem 274: 36995-37003, 1999.
14. INOUE T, HOSHI K, YAGUCHI I, IWASAKI Y, TAKAYANAGI K, MOROOKA S: Serum levels of circulating adhesion molecules after coronary angioplasty. Cardiology 91: 236-242, 1999.
15. JESTY J, LORENZ A, RODRIGUEZ J, WUN TC: Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor. Blood 87: 2301-2307, 1996.
16. LEVI M, TEN CATE H: Disseminated intravascular coagulation. N Engl J Med 341: 586-592, 1999.
17. LI A, CHANG AC, PEER GT, WUN TC, TAYLOR FB Jr: Recombinant tissue factor pathway inhibitor enhances the binding of factor Xa to human monocytes. Thromb Haemost 85: 830-836, 2001
18. LINDAHL AK. Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle. Cardiovasc Res 33: 286-291, 1997.
19. LINDHOUT T, FRANSSEN J, WILLEMS G: Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor. Thromb Haemost 74: 910-915, 1995.
20. MORRISSEY JH, NEUENSCHWANDER PF, HUANG Q, MCCALLUM CD, SU B, JOHNSON AE: Factor VIIa-tissue factor: functional importance of protein/membrane interactions. Thromb Haemost 78: 112-116, 1997.
21. O'MALLEY T, LUDLAM CA, RIEMERMSA RA, FOX KAA: Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1). Potential risk factor for the acute coronary syndromes. Eur Heart J 22: 1226-1234, 2001.
22. RAPAPORT SI, RAO LV: The tissue factor pathway: how it has become a "prima ballerina". Thromb Haemost 74: 7-17, 1995.
23. SALEMINK I, FRANSSEN J, WILLEMS GM, HEMKER HC, LI A, WUN TC, LINDHOUT T: Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity. Thromb Haemost 80: 273-280, 1998.
24. SANDSET PM, BENDZ B, HANSEN JB: Physiological function of tissue factor pathway inhibitor and its interaction with heparins. Haemostasis 30 (Suppl 2): 48-56, 2000.
25. SANDSET PM. Tissue factor pathway inhibitor - an update. Haemostasis 26 (Suppl 4): 154-165, 1996.
26. SIMPSON PJ, FANTONE JC, MICKELSON JK, GALLAGHER KP, LUCCHESI BR: Identification of a time window for therapy to reduce experimental canine myocardial injury: suppression of neutrophil activation during 72 hours of reperfusion. Circ Res 63: 1070-1079, 1988.
27. SINGH N, GEMMEL CH, DALY RA, YEO EL: Elevated platelet-derived microparticle levels during unstable angina. Can J Card. 11: 1015-1021, 1995.
28. TOSCHI V, GALLO R, LETTINO M, FALLON JT, GERTZ SD, FERNANDEZ-ORTIZ A, CHESEBRO JH, BADIMON L, NEMERSON Y, FUSTER V, BADIMON JJ: Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95: 594-599, 1997.
29. WEISS HJ, HOFFMANN T, TURITTO VT, NEMERSON Y: Further studies on the presence of functional tissue factor activity on subendothelium of normal human and rabbit arteries. Thromb Res. 73: 313-326, 1994.
30. WESTRICK RJ, BODARY PF, XU Z, SHEN YC, BROZE GJ, EITZMAN DT: Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 103: 3044-3046, 2001.
31. WILCOX JN, SMITH KM, SCHWARTZ SM, GORDON D: Localization of tissue factor in normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 86: 2839-2843, 1989.
32. YAMAZAKI T, SEKO Y, TAMATANI T, MIYASAKA M, YAGITA H, OKUMURA K, NAGAI R, YAZAKI Y: Expression of intercellular adhesion molecule-1 in rat heart with ischaemia/reperfusion and limitation of infarct size by treatment with antibodies against cell adhesion molecules. Am J Pathol 143: 410-418, 1993.